Key facts
- Chirality Biosciences’s last known valuation is $14.0M (Oct 2025).
- It has raised $3.1M across 1 recorded rounds; the latest was Seed Round ($3.1M) in Oct 2025.
- Notable investors include Pioneer Fund.
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Chirality Biosciences
Funding rounds
1 roundsAbout Chirality Biosciences
Developer of a pharmaceutical refinement technology designed for safer drug produce and reduced adverse effects. The company's platform utilises proprietary chiral separation methods to produce purer active pharmaceutical ingredients, minimise waste, accelerate production timelines, enabling biotechnology firms and drug manufacturers to deliver high-efficacy treatments with fewer side effects, improved patient outcomes, and scalable processes that bypass legacy chemical purification systems.
- Sector
- Healthcare
- HQ
- Farmingdale, NY, United States
- Founded
- 2023
- Employees
- 2
- Website
- chirality.com/
- Ownership
- Privately Held (backing)
Chirality Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chirality Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chirality Biosciences in its N-PORT filings yet. We sweep new filings monthly.